Cerus (NASDAQ:CERS) is up 26% after hours on robust volume on the heels of its announcement of positive results from a Phase 3 clinical trial, SPARC, assessing the safety and efficacy of transfused INTERCEPT-treated red blood cells (RBCs) in thalassemia patients.
The results demonstrated non-inferiority between INTERCEPT-treated RBCs and conventional RBCs.
Complete results will be submitted for presentation at upcoming scientific conferences and for publication.
An application for CE Mark certification should be filed in H2.
Management will host a conference call tomorrow, January 24, at 8;30 am ET to discuss the results.
Now read: BeiGene: A Promising Start To 2018 »
Subscribe for full text news in your inbox